Cancer Localization in the Prostate with F-18 Fluorocholine Positron Emission Tomography. Addendum
Final rept. 20 Dec 2008-19 Dec 2009
QUEEN'S MEDICAL CENTER HONOLULU HI
Pagination or Media Count:
The project evaluated fluorine-18 18F- fluorocholine positron emission tomography PET as an imaging technique for delineating malignancy in the prostate gland. The technique measures tissue metabolism of fluorocholine, a substrate that is preferentially metabolized by cancer cells due to malignant over-expression of the choline transporter and choline kinase enzyme. Based on this measurement, it was proposed that cancerous tissue can be differentiated from benign tissue in the prostate. Project Scope Men with prostate cancer undergoing radical prostatectomy surgery underwent pre-operative PET scanning to measure fluorocholine uptake in the prostate gland. Imaging results were compared to histopathologic analyses of the prostatectomy specimen to determine the accuracy of prostate cancer sextant localization based on measured fluorocholine uptake. Recruitment of human subjects for this project was completed in 2008. Histologic and immunohistochemical analysis of prostate specimens was performed at the Armed Forces Institute of Pathology. Two subsequent research projects have been derived from the outcome this project. The first project is a research collaboration to develop clinically-oriented image analysis tools for measuring the kinetics of 18F-fluorocholine activity in the prostate gland using PETCT. The second project is a National Cancer Institute-funded study to conduct clinical trials assessing the treatment response to chemotherapy and anti-androgen therapy using 18F-fluorocholine PETCT in men with advanced prostate cancer.
- Anatomy and Physiology
- Medicine and Medical Research